Development Programme

Introduction.

PresSura is developing a single compound, EU-C-001, across a number of neurological conditions in which a rise in intracranial pressure and other proteins plays a central role.

Moderate to Severe
Traumatic Brain Injury

EU-C-001 is in a Phase 2A double-blind trial in moderate to severe TBI across multiple countries. The trial has completed enrolment and follows a Phase 1 programme and an open-label phase.

Stroke and Other
Neurological Conditions

PresSura is targetting stroke as a leading indication in its development program. A preclinical primary pharmacology programme has been completed and a full Phase 1 safety data package in healthy volunteers is available. Plans for a Phase 2A Proof of Concept study are in development.

Concussion Related
Conditions

PresSura is targeting mild TBI (concussion) building on its current moderate to severe TBI trial. A focussed preclinical primary pharmacology programme in concussion and a Phase 1 in healthy volunteers are complete; a Phase 2A programme in mTBI is being planned.

Portfolio.

PRECLINICAL

PHASE 1

PHASE 2A

PHASE 3

Moderate/severe TBI

Phase 2A – PANGEA Study

Stroke

Phase 1 Completed

Concussion / PCS

Phase 1 Completed

IP.

A strong IP portfolio covering the various indications, with patent life ranging from 2034 to 2040. IP managed through Davies Collison Cave, a leading international IP firm headquartered in Melbourne.

Portfolio.

IP.

A strong IP portfolio covering the various indications, with patent life ranging from 2034 to 2040. IP managed through Davies Collison Cave, a leading international IP firm headquartered in Melbourne.